ClinicalTrials.gg
RecruitingNCT07718737Updated Oct 26, 2026

Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

A Phase 2/3 interventional study of AMT-116 and Investigator's choice regimens (docetaxel or docetaxel plus ramucirumab) in NSCLC (Advanced Non-small Cell Lung Cancer), sponsored by Multitude Therapeutics Inc.. Recruiting at 7 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Multitude Therapeutics Inc. · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Oct 26, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
512
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 499 studies in Carcinoma, Non-Small-Cell Lung with a site in Australia — 123 open to participants now, 214 under way, 83 of them phase 3. Carcinoma, Non-Small-Cell Lung · Australia.

Planned enrollment
152nd of 486
512 · median 271
Started
2026
with 30 others
Phase 2/3
12 of 499
5 open now
Primary completion
2028-03
later than 123 of 213 live
Registered
495th of 499
by date

Among the 499 studies in Carcinoma, Non-Small-Cell Lung with a site in Australia, this one is the 152nd largest by planned enrollment of the 486 interventional ones that give a count, is one of 31 that started in 2026, is one of 12 in phase 2/3, reaches primary completion later than 123 of the 213 other live ones, and was the 495th registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

123 of the 499 studies in Carcinoma, Non-Small-Cell Lung with a site in Australia are open now. Recruiting first, the newest first:

117 more — sign in →

All 123 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 499 studies in Carcinoma, Non-Small-Cell Lung with a site in Australia, or all of them as a file.
02

Study summary

This clinical trial consists of two parts: phase 2 and phase 3.

The goal of phase 2 of this clinical trial is to compare which dose level of AMT-116 works better to treat advanced or metastatic non-squamous EGFR-Wildtype non-small cell lung cancer (NSCLC) in adults. It will also learn about the safety of AMT-116. The main questions it aims to answer are:

  • Which level of AMT-116 works better to treat advanced or metastatic non-squamous EGFR-Wildtype NSCLC?
  • What medical problems do participants have when taking AMT-116? The goal of phase 3 of this clinical trial is to compare AMT-116 to study doctor's choice (a kind of retainable treatment for you in the opinion of the study doctor) to see if AMT-116 works better to treat advanced or metastatic non-squamous EGFR-Wildtype NSCLC.

In both parts of this trial, participants will receive AMT-116 or study doctor's choice every 2 weeks until the study doctor thinks you are benefiting from your participation or until your disease progresses or you are unable to tolerate the study drug

03

Conditions studied

  • NSCLC (Advanced Non-small Cell Lung Cancer)
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily agree to join this clinical trial, sign the form, and follow all trial arrangements, including scheduled hospital visits, examinations and other study requirements.
  2. Age between 18 and 80 years old (including 18 and 80 years old) at the time of signing the informed consent form.
  3. Diagnosed with non-squamous non-small cell lung cancer (NSCLC) confirmed by pathological or cytological tests. The disease must be either locally advanced and unresectable (not suitable for radical chemoradiotherapy) or advanced lung cancer.
  4. Must have a clear EGFR gene test result before enrollment. Patients with other actionable gene mutations (excluding EGFR mutation) are eligible. Testing for other genes is not mandatory, and can be performed according to local hospital routine standards and available treatment options.
  5. Have received no more than one for advanced or metastatic lung cancer. or adjuvant chemotherapy will be counted as one prior chemotherapy line if the disease progresses within 6 months after the end of treatment.
  6. Have received at least one prior formal treatment (chemotherapy, targeted therapy or immunotherapy) for advanced or metastatic lung cancer, with subsequent disease progression or recurrence. Participants must meet the corresponding requirements based on their genetic status:

    6.1 Patients without any actionable gene mutations: Have experienced disease progression after platinum-based chemotherapy and therapy (used alone or combined with chemotherapy), or are not suitable for the above two treatments clinically.

    6.2 Patients with gene mutations that do not routinely use immunotherapy (e.g., ALK fusion): Have experienced disease progression after targeted therapy for gene mutations and platinum-based chemotherapy, or are not suitable for the above two treatments clinically.

    6.3 Patients with gene mutations for which immunotherapy is a conventional treatment: Have also experienced disease progression after immune checkpoint inhibitor therapy (used alone or combined with chemotherapy), or are not suitable for immunotherapy clinically.

  7. The investigator confirms that the patient is suitable for docetaxel treatment (only applicable for Phase 3 trial).
  8. Have at least one measurable tumor lesion assessed by 1.1 criteria.
  9. physical status score is 0 or 1, with normal daily physical activity.
  10. Expected survival time is at least 12 weeks.
  11. Have normal and stable organ function. No blood transfusion, erythropoietin, thrombopoietin, granulocyte colony-stimulating factor or other supportive treatment within 14 days before the test, and meet the following laboratory standards:

    • Blood routine: ≥ 1.5 × 10/L; count ≥ 100 × 10/L; ≥ 90 g/L
    • Renal function: ≥ 50 mL/min (calculated by Cockcroft-Gault formula)
    • Liver function: Total ≤ 1.5 times the (or ≤ 3 times the upper limit of normal for patients with Gilbert's disease); and ALT ≤ 2.5 times the upper limit of normal (or ≤ 5 times the upper limit of normal for patients with liver metastases)
    • Coagulation function: or aPTT ≤ 1.5 times the upper limit of normal for patients not receiving anticoagulant treatment
  12. Female patients of childbearing age must use two effective methods during the trial treatment period and within 12 weeks after the last dose of trial drug. A negative serum pregnancy test is required within 7 days before enrollment. women (no menstruation for 12 consecutive months) or surgically sterilized women are exempted.
  13. Male patients must use latex condoms during treatment and within 12 weeks after the last dose of trial drug (even after vasectomy). All patients are prohibited from donating sperm (male) or eggs (female) during the trial and within 12 weeks after the last drug dose.

Exclusion criteria

Exclusion Criteria:

  • I. General Exclusion Criteria (Applicable to All Phases)

    1. Prior treatment with antibody-drug conjugates (ADCs) based on topoisomerase 1 inhibitors.
    2. Receipt of any systemic anti-cancer therapy within the shorter period between five half-lives of the drug or 21 days prior to randomization is prohibited.

      Notes:

      ① If the half-life of an agent has not been determined, its administration within 21 days prior to randomization is not allowed.

      ② Patients receiving bisphosphonates or denosumab may continue these medications during the study and are not excluded.

    3. Tumor pathology confirms adenosquamous, neuroendocrine, or sarcomatoid features.
    4. Presence of actionable activating mutations in the epidermal growth factor receptor (EGFR) gene.
    5. Non-small cell lung cancer (NSCLC) patients who are eligible for definitive local therapy alone (e.g., selected stage IIIA patients) are excluded.
    6. Central nervous system (CNS) :

      ① Patients with are eligible only if all the following conditions are fully met: the CNS metastases have been treated with surgical resection and/or radiotherapy at least 28 days prior to randomization; and post-treatment evaluation satisfies all three requirements below: (1) No cerebral edema is observed in screening examinations, and no ongoing need for systemic or anticonvulsant medications; (2) Neurological symptoms are absent or stable (Grade ≤ 1); (3) Follow-up imaging conducted within 28 days prior to randomization shows no progression of treated lesions and no new lesions.

      ② Note: Patients with a history of are strictly excluded.

    7. Unresolved toxicities of Grade > 1 caused by prior systemic anti-cancer treatment.

      Note: Patients with Grade ≤ 2 peripheral neuropathy, alopecia of any grade, endocrinopathy well-managed by hormone replacement therapy, or other toxicities judged to pose no safety risks by the investigator are eligible for enrollment.

    8. Receipt of wide-field radiotherapy (e.g., irradiation covering more than 30% of bone marrow-bearing bones) within 28 days prior to randomization, or palliative radiotherapy for symptom control within 2 weeks prior to randomization.
    9. Undergoing major surgery (excluding vascular access device placement and tumor ) within 28 days prior to randomization, or failure to fully recover from postoperative side effects of such surgery.
    10. Presence of severe cardiac diseases, including myocardial infarction or acute coronary syndrome (including unstable angina) within 6 months prior to randomization, (NYHA) Class III/IV congestive heart failure, uncontrolled hypertension, or uncontrolled cardiac arrhythmia.
    11. History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis; or active pneumonitis identified on screening chest computed tomography (CT). A history of radiation-induced pulmonary fibrosis within the previous radiation field is permitted.
    12. History of thromboembolic or cerebrovascular events within 6 months prior to randomization, including , stroke, deep vein thrombosis (DVT), and pulmonary embolism (PE).

      Note: Patients diagnosed with DVT or PE within the above 6-month window may be eligible if they have received standardized anticoagulant treatment (or discontinued anticoagulants when clinically unnecessary) and show no evidence of active disease at screening.

    13. Presence of acute or bacterial, fungal, or viral infections, including active (HBV), (HCV), or confirmed (HIV) infection.

      Note: Patients with chronic HBV, HCV, or HIV infection may be enrolled upon mutual approval by the investigator and sponsor, provided they meet one of the following criteria:

      1. HIV-positive patients have received stable antiretroviral therapy (ART) for at least 28 days, with ≥ 350 cells/μL and HIV viral load \< 400 copies/mL;
      2. Patients with chronic HBV infection are on concurrent anti-HBV treatment with HBV viral load below the quantitative limit;
      3. Patients with prior HCV infection have completed curative anti-HBV treatment with HCV viral load below the quantitative limit;
      4. Patients receiving ongoing anti-HCV treatment have HCV viral load below the quantitative limit.
    14. Receipt of within 28 days prior to randomization.
    15. Requirement for concurrent treatment with strong or moderate cytochrome P450 3A4 () inhibitors within 1 week prior to the first study drug dose or during the entire treatment period (see Appendix 6 for detailed list).
    16. Known or suspected intolerance or to any components of the investigational medicinal product (IMP).
    17. Active alcohol or illicit drug abuse.
    18. Female patients who are pregnant or breastfeeding.
    19. Presence of any mental or medical condition that impairs the ability to provide or comply with trial requirements; or any severe acute/chronic medical, psychiatric disease or laboratory abnormality that may increase trial-related risks, interfere with study result interpretation, or is deemed inappropriate for enrollment by the investigator.
    20. History of other malignant tumors (excluding the study indication cancer) within 5 years prior to randomization.

      Note: Patients with adequately treated basal cell skin cancer, non-invasive superficial bladder cancer, cervical carcinoma in situ, breast carcinoma in situ, or prostate carcinoma in situ are eligible if no active disease has been observed for 2 years prior to randomization.

      II. Phase 3 Specific Exclusion Criteria

    21. Prior treatment with docetaxel as monotherapy or combination therapy.
    22. Radiological evidence of major blood vessel invasion or encasement by tumor.
    23. Radiological evidence of intratumoral cavitation.
    24. History of uncontrolled hereditary or acquired thrombotic disorders.
    25. Receipt of therapeutic anticoagulation with warfarin, low-molecular-weight heparin, or similar agents. Patients receiving low-dose prophylactic anticoagulation are eligible if they meet the coagulation parameter requirements specified in inclusion criterion 11.
    26. Receipt of continuous antiplatelet or anticoagulant therapy (excluding prophylactic anticoagulation for venous patency maintenance) within 2 weeks prior to randomization. Aspirin at a daily dose of up to 325 mg is permitted.
    27. Presence of severe unhealed wounds, ulcers, or bone fractures within 28 days prior to randomization.
    28. Presence of significant bleeding disorders, vasculitis, or Grade 3/4 gastrointestinal bleeding within 3 months prior to randomization.
    29. History of gross hemoptysis (defined as bright red blood sputum or blood volume ≥ 1/2 teaspoon) within 2 months prior to randomization.
    30. History of gastrointestinal perforation and/or fistula formation within 6 months prior to randomization.
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
512 participants (estimated)

Study arms

  • Experimental
    AMT-116 4 mg/kg

    Drug: AMT-116

  • Experimental
    AMT-116 5 mg/kg

    Drug: AMT-116

  • Active comparator
    Investigator's choice of therapy (docetaxel or docetaxel plus ramucirumab)

    Drug: Investigator's choice regimens (docetaxel or docetaxel plus ramucirumab)

Interventions

  • AMT-116 will be administered at 4 mg/kg or 5 mg/kg as an intravenous (IV) infusion on Day 1 of each 2-week cycle.

  • DrugInvestigator's choice regimens (docetaxel or docetaxel plus ramucirumab)

    Docetaxel will be administered as an IV infusion of 75 mg/m2 over approximately 60 minutes on Day 1 of each 3-week cycle. Ramucirumab will be administered as an IV infusion of 10 mg/kg over 30-60 minutes on Day 1 of each 3-week cycle prior to docetaxel

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events as Assessed by CTCAE v6.0

    Time frame: About 7 months

Secondary outcomes

  1. Objective response rate (ORR)

    Time frame: About 6 months

  2. Progression free survival (PFS)

    Time frame: About 6 months

  3. Duration of response (DOR)

    Time frame: About 6 months

  4. Disease control rate (DCR)

    Time frame: About 6 months

  5. Peak and pre-dose trough concentrations (Cmax and Ctrough) over time for conjugated antibody

    Time frame: About 6 months

  6. Peak and pre-dose trough concentrations (Cmax and Ctrough) over time for total antibody

    Time frame: About 6 months

  7. Peak and pre-dose trough concentrations (Cmax and Ctrough) over time for released free payload

    Time frame: About 6 months

  8. Peak and pre-dose trough concentrations (Cmax and Ctrough) over time for the anti-drug antibodies (ADAs)

    Time frame: About 6 months

  9. Overall survival

    Time frame: About 12 months

Other outcomes

  1. Correlation of PFS with baseline tumor CD44v9 expression

    Time frame: About 12 months

  2. Correlation of ORR with baseline tumor CD44v9 expression

    Time frame: About 12 months

  3. Correlation of DOR with baseline tumor CD44v9 expression

    Time frame: About 12 months

  4. Correlation of DCR with baseline tumor CD44v9 expression

    Time frame: About 12 months

07

Study locations

1 of 7 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Mar 2028, 18 months after the start.

Of 56 phase 2/3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 40. This study's planned 18 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Oct 26, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2026
First posted
Jul 22, 2026
StartActual
Sep 30, 2026was Aug 2026
Primary completionEst.
Mar 30, 2028
CompletionEst.
Dec 30, 2028
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 26, 2026
Sites
7 sites changed recruiting status (6 now not yet recruiting, 1 now recruiting)
Show 7 sites
  • Hematology Oncology Associates of the Treasure Coast · Port Saint Lucie, United Statesno status→Not yet recruiting
  • Lumi Research · Kingwood, United Statesno status→Not yet recruiting
  • Coffs Harbour Health Campus · Coffs Harbour, Australiano status→Not yet recruiting
  • Austin Health (Olivia Newton John Cancer Centre) · Melbourne, Australiano status→Not yet recruiting
  • St Vincent's Hospital Melbourne · Melbourne, Australiano status→Not yet recruiting
  • Calvary Mater Newcastle · Newcastle, Australiano status→Not yet recruiting
  • Macquarie University Hospital · Sydney, Australiano status→Recruiting
Oct 26, 2026
Start date
Aug 28, 2026→Sep 30, 2026 (actual)
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Not yet recruiting→Recruiting
    7 sites changed recruiting status (6 now not yet recruiting, 1 now recruiting)
    Show 7 sites
    • Hematology Oncology Associates of the Treasure Coast · Port Saint Lucie, United Statesno status→Not yet recruiting
    • Lumi Research · Kingwood, United Statesno status→Not yet recruiting
    • Coffs Harbour Health Campus · Coffs Harbour, Australiano status→Not yet recruiting
    • Austin Health (Olivia Newton John Cancer Centre) · Melbourne, Australiano status→Not yet recruiting
    • St Vincent's Hospital Melbourne · Melbourne, Australiano status→Not yet recruiting
    • Calvary Mater Newcastle · Newcastle, Australiano status→Not yet recruiting
    • Macquarie University Hospital · Sydney, Australiano status→Recruiting
    Start date Aug 28, 2026→Sep 30, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07718737
Lead sponsor
Multitude Therapeutics Inc.
Responsible party
Sponsor
First posted
Jul 22, 2026
Start date
Sep 30, 2026
Primary completion
Mar 30, 2028 (estimated)
Completion
Dec 30, 2028 (estimated)
Last update
Oct 26, 2026

Study contacts

Yanhong Fu
Contact
yanhong.fu@multitudetherapeutics.com
+86 13952922547

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-CD44v9 Antibody-drug Conjugate AMT-116

Start the discussion